PMID- 32185517
OWN - NLM
STAT- MEDLINE
DCOM- 20211013
LR  - 20211013
IS  - 1435-5922 (Electronic)
IS  - 0944-1174 (Print)
IS  - 0944-1174 (Linking)
VI  - 55
IP  - 5
DP  - 2020 May
TI  - Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic 
      review.
PG  - 496-514
LID - 10.1007/s00535-020-01680-0 [doi]
AB  - Nucleos(t)ide analogues (NAs) are the main drug category used in chronic 
      hepatitis B (CHB) treatment. Despite the fact that NAs have a favourable safety 
      profile, undesired adverse events (AEs) may occur during the treatment of CHB. 
      Given the eminent number of patients currently receiving NAs, even a small risk 
      of any of these toxicities can represent a major medical issue. The main 
      objective of this review was to analyse information available on AEs associated 
      with the use of NAs in published studies. We choose the following MesH terms for 
      this systematic review: chronic hepatitis B, side effects and treatment. All 
      articles published from 1 January 1990 up to 19 February 2018 in MEDLINE of 
      PubMed, EMBASE, the Cochrane Library and LILACS databases were searched. A total 
      of 120 articles were selected for analysis, comprising 6419 patients treated with 
      lamivudine (LAM), 5947 with entecavir (ETV), 3566 with tenofovir disoproxil 
      fumarate (TDF), 3096 with telbivudine (LdT), 1178 with adefovir dipivoxil (ADV) 
      and 876 with tenofovir alafenamide (TAF). The most common AEs in all NAs assessed 
      were abdominal pain/discomfort, nasopharyngitis/upper respiratory tract 
      infections, fatigue, and headache. TAF displays the highest density of AEs per 
      patient treated among NAs (1.14 AE/treated patient). In conclusion, treatment of 
      CHB with NAs is safe, with a low incidence of AEs. Despite the general 
      understanding TAF being safer than TDF, the number of patients treated with TAF 
      still is too small in comparison to other NAs to consolidate an accurate safety 
      profile. PROSPERO Registration No. CRD42018086471.
FAU - de Fraga, Raquel Scherer
AU  - de Fraga RS
AD  - Department of Gastroenterology, University of Sao Paulo School of Medicine, Av. 
      Dr. Eneas Carvalho de Aguiar, 255 ICHC, 9th floor, Office 9159, Sao Paulo, SP, 
      05403-000, Brazil. rschfraga@gmail.com.
AD  - IMED School of Medicine, Passo Fundo, RS, Brazil. rschfraga@gmail.com.
FAU - Van Vaisberg, Victor
AU  - Van Vaisberg V
AD  - Department of Gastroenterology, University of Sao Paulo School of Medicine, Av. 
      Dr. Eneas Carvalho de Aguiar, 255 ICHC, 9th floor, Office 9159, Sao Paulo, SP, 
      05403-000, Brazil.
FAU - Mendes, Luiz Claudio Alfaia
AU  - Mendes LCA
AD  - Division of Clinical Gastroenterology and Hepatology, Hospital das Clinicas, 
      University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil.
FAU - Carrilho, Flair Jose
AU  - Carrilho FJ
AD  - Department of Gastroenterology, University of Sao Paulo School of Medicine, Av. 
      Dr. Eneas Carvalho de Aguiar, 255 ICHC, 9th floor, Office 9159, Sao Paulo, SP, 
      05403-000, Brazil.
AD  - Division of Clinical Gastroenterology and Hepatology, Hospital das Clinicas, 
      University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil.
FAU - Ono, Suzane Kioko
AU  - Ono SK
AD  - Department of Gastroenterology, University of Sao Paulo School of Medicine, Av. 
      Dr. Eneas Carvalho de Aguiar, 255 ICHC, 9th floor, Office 9159, Sao Paulo, SP, 
      05403-000, Brazil.
AD  - Division of Clinical Gastroenterology and Hepatology, Hospital das Clinicas, 
      University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200317
PL  - Japan
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
RN  - 0 (Antiviral Agents)
RN  - 0 (Nucleosides)
RN  - 0 (Nucleotides)
SB  - IM
MH  - Antiviral Agents/administration & dosage/*adverse effects
MH  - Hepatitis B, Chronic/*drug therapy
MH  - Humans
MH  - Nucleosides/administration & dosage/adverse effects
MH  - Nucleotides/administration & dosage/adverse effects
PMC - PMC7188775
OTO - NOTNLM
OT  - Adverse events
OT  - Chronic hepatitis B
OT  - Nucleotide/nucleoside analogues
COIS- The authors declare that they have no conflict of interest.
EDAT- 2020/03/19 06:00
MHDA- 2021/10/14 06:00
PMCR- 2020/03/17
CRDT- 2020/03/19 06:00
PHST- 2019/07/01 00:00 [received]
PHST- 2020/02/26 00:00 [accepted]
PHST- 2020/03/19 06:00 [pubmed]
PHST- 2021/10/14 06:00 [medline]
PHST- 2020/03/19 06:00 [entrez]
PHST- 2020/03/17 00:00 [pmc-release]
AID - 10.1007/s00535-020-01680-0 [pii]
AID - 1680 [pii]
AID - 10.1007/s00535-020-01680-0 [doi]
PST - ppublish
SO  - J Gastroenterol. 2020 May;55(5):496-514. doi: 10.1007/s00535-020-01680-0. Epub 
      2020 Mar 17.